

Application of Diazodecomposition Reactions in Tandem With [2,3]-Sigmatropic Rearrangements To Prepare Substituted Azabicyclic Ring Systems

Thomas A. Chappie[†], R. Matt Weekly, and Mark C. McMills*

Department of Cliemistry, Ohio University, Athens, Ohio 45701

Abstract: Stereospecific [2,3]-Sigmatropic rearrangements occurring *via* ylides generated from the decomposition of α -diazoamides provided good yields of substituted azabicyclo[3.3.0]octanes. In addition some of the non-rearranged cyclopropanes were formed. Copyright © 1996 Elsevier Science Ltd

Over the past several years diazodecomposition reactions have become synthetically productive methods of forming carbon-carbon bonds when used in tandem with either sigmatropic rearrangements or cycloadditions. Ando^{1a,b}, Doyle^{2a,b}, Padwa^{3a,b} and others have demonstrated the utility of electrophilic metallocarbenoid species for the formation of transient ylides. Nucleophiles such as sulfur, oxygen, and nitrogen add easily to the metallocarbenoid center, generating an ylide capable of further reaction. In a series of elegant studies, Kido and Kato have shown that sigmatropic rearrangement of large cyclic ylide intermediates can be used to prepare linearly-fused or bridged-bicyclic lactones.^{4a-e} Despite the extensive investigations by Kido and Kato, very little is known for systems utilizing cyclic templates or substrates used to prepare amine or amide derivatives. We report here the preparation of functionalized azabicyclo[3.3.0]octane skeletons with a high degree of stereocontrol.



For this initial study, medium-sized ylide rings such as 2, generated from a precursor diazoamide 1, were chosen to accomplish the intramolecular [2,3]-sigmatropic rearrangement to prepare smaller azabicyclic rings (i.e. eightmembered ylide contracts to form a pyrrolidinone ring). It is proposed that the stereochemistry of the double bond and the R group attached to the diazo-containing center of diazoamide 1 would play an important role in the production of an intermediate ylide.



a) (CF₃CH₂O)₂POCH₂CO₂CH₃, KHMDS, 18-C-6, -78°C, 10:1 cis, 77% b) (CH₃O)₂POCH₂CO₂CH₃, nBuLi, 2:1 trans, 77-82% c) DIBAL, -78°C, 90-95% d) (PhS)₂, (Bu)₃P, 84% e) TFA then diketene, 80-85% f) pCH₃CONHPhSO₂N₃, DBU, 96% g) 5% NaOH, CH₃OH, 80-89%

Proline was chosen as a simple template for formation of a linearly-fused azabicyclic system. Diazoamide **5a** is easily prepared by a five step sequence starting from the known BOC-protected prolinal **4**. The proline ring provides a suitable 1,2-disubstituted template for the formation of an eight-membered cyclic ylide intermediate. In addition, preparation of both the *cis* and *trans* disubstituted olefins, as well as the ability to place different nucleophilic atoms at the allylic position of the olefinic tether is easily accomplished utilizing the carboxyl group of proline. It was expected that upon sigmatropic rearrangement of the ylide, the convex/concave nature of the cyclic intermediate would stereospecifically produce the azabicyclo[3.3.0]octane ring system with the newly formed substituents *syn* to the hydrogen α to nitrogen.



a) 5 mole% based on 5b b) Slow addition (20 mg/1h) of 5b as a .01M solution to a refluxing solution of the catalyst in solvent c) Purified by column chromatography, yields are combined overall d) Some ratios based on GC-MS analysis of the crude reaction mixture

In an attempt to destabilize the diazo containing center relative to the series of α -diazoamides 5a and 6a with electron withdrawing substituents, the acetyl side chains of 5a and 6a were removed under basic conditions (5% NaOH, MeOH) and the resulting diazoamide 5b was submitted to various diazodecomposition conditions including a number of different catalysts and solvents. Reaction of 5b with both dirhodium and copper catalyst in benzene resulted in the formation of a predominance of the pyrrolizidine-cyclopropane 7 rather than the expected azabicyclooctane 8⁵ (1.4 - 11 : 1). Interestingly, only one of the two possible cyclopropanes forms in the reaction sequence. We speculate that this may be due to non-bonded interactions making only one rotamer reactive or possibly the reaction is under product control. Despite the elegant studies conducted by Doyle and Padwa, a simple change in the electronic nature of the ligands attached to rhodium provided little difference in the product ratio toward formation of the azabicyclooctane 8⁶ It was determined that changing the polarity of the solvent might help to stabilize a more polar transition state thereby producing the azabicyclooctane 8 in excess of the pyrrolizidine-cyclopropane 7. *Catalytic rhodium caprolactamate with either fluorobenzene or dichloroethane as solvent resulted in a complete turnover of the product ratio toward a predominance of the azabicyclooctane 8(6 - 15 : 1, 55-60% yield)*.



a) 5 mole% based on 6b b) Slow addition (20 mg/1h) of 5b as a 0.01M solution to a refluxing solution of the catalyst in solvent c) Purified by column chromatography, yields are combined overall d) Some ratios based on GC-MS analysis of the crude reaction mixture

The role that olefin geometry might play in attack of the metallocarbenoid intermediate was also investigated. It was determined from simple modeling that the *trans* olefin may place the allylic nucleophile too distant to interact with the electrophilic carbenoid center, therefore the only product that might be isolated from diazodecomposition of amide **6b** would be the cyclopropanes **10** and **11**. *Amazingly, when decomposed with electron rich catalyst rhodium caprolactamate,* α *-diazoamide 6b formed the anti pyrrolizidine 9.⁷ It was also discovered that diazodecomposition of trans diazoamide 6b with the electron withdrawing ligands attached to rhodium or with palladium catalysis produced <u>only</u> cyclopropanes 10 and 11⁸ (59-78%, 2.1-2.9 : 1 ratio) with none of the sigmatropic rearrangement product formed.*

We have demonstrated the utility of diazodecomposition/tandem [2,3]-rearrangements with cyclic diazoamide systems forming substituted azabicyclo[3.3.0]octane and cyclopropanated pyrrolizidine products. It has been noted that both the catalyst and solvent as well as the diazoamide substrate are critical in determining the pathway followed by the metallocarbenoid intermediate.

ACKNOWLEDGEMENT: The authors would like to thank the Ohio University Research Committee and Ohio University for start-up funds and continuing support. The authors would also like to thank Professor Mike Doyle for helpful discussions.

REFERENCES

† Current address: Central Research Division, Pfizer Inc., Eastern Point Rd, Groton, CT 06340

- a) Ando, W. Acc. Chem. Res. 1977, 10, 179-85. b) Ando, W.; Yagihara, T.; Tozune, S.; Imai, I.; Suzuki, J.; Toyama, T.; Nakaido, S.; Migita, T. J. Org. Chem. 1972, 37, 1721-7.
- (2) a) Doyle, M. P. Acc. Chem. Res. 1986, 19, 348-56. b) Doyle, M. P. Chem. Rev. 1986, 86, 919-40.
- (3) a) Padwa, A.; Hornbuckle, S. F. Chem. Rev. 1991, 91, 263-309. b) Padwa, A. Acc. Chem. Res. 1991, 24, 22-28.
- (4) a) Kido, F.; Sinha, S. C.; Abiko, T.; Watanabe, M.; Yoshikoshi, A. Tetrahedron 1990, 46, 4887-906. b) Kido, F.;
 Kawada, Y.; Kato, M.; Yoshikoshi, A. Tetrahedron Lett. 1991, 32, 6159-62. c) Kido, F.; Kazi, A. B.; Yamaji, K.; Kato, M.; Yoshikoshi, A. Heterocycles 1992, 33, 607-18. d) Kido, F.; Yamaji, K.; Sinha, S. C.; Yoshikoshi, A.; Kato, M. J.

Chem. Soc., Chem. Commun. 1994, 789-90. e) Kido, F.; Abiko, T.; Kazi, A. B.; Sinha, S. C.; Kato, M.; Yoshikoshi, A. Tennen Yuki Kagobutsu Toronkai Koen Yoshishu 1990, 32, 433-40.

- (5) Spectral data for Syn-pyrrolizidine 8: ¹H NMR (400 MHz, CDCl₃) δ 7.55 7.19 (m, 5H, -C₆H₅), 6.09 (ddd, *J* = 17.3, 10.4, 7.2 Hz, 1H, -CH=CHH), 5.21 (dt, *J* = 10.4, 1.2Hz, 1H, -CH=CHH), 5.16 (dt, *J* = 17.2, 1.2 Hz, 1H, CH=CHH), 3.91 (d, *J* = 7.2 Hz, 1H, S-CH-), 3.70 (dt, *J* = 5.7, 8.4 Hz, 1H, N-CH-), 3.55 (dt, *J* = 11.9, 7.5 Hz, 1H, N-CHH-), 3.05 (m, 1H, N-CHH-), 2.94 (dd, *J* = 8.5, 7.4 Hz, 1H, N-CH-CH-), 2.02 (m, 3H, -CH₂-CHH-), 1.25 (m, 1H, -CH₂-CHH-); ¹³C NMR (100.58 MHz, CDCl₃) δ 171.9, 134.2, 132.4, 130.2, 128.8, 127.6, 118.2, 64.1, 57.8, 52.6, 41.5, 30.3, 26.9; IR (neat) 1696; MS (70 eV) 259, 149, 136, 120, 109, 94, 77, 70, 53, 41; High Resolution MS *m*/z calculated for C₁₅H₁₇NOS (M⁺) 259.1031. found 259.1028.
- (6) Padwa, A.; Austin, D. J.; Hornbuckle, S. F.; Semones, M. A.; Doyle, M. P.; Protopopova, M. N. J. Am. Chem. Soc. 1992, 114, 1874-6.
- (7) Spectral data for Anti pyrrolizidine 9: ¹H NMR (400 MHz, CDCl₃) δ 7.32 (m, 5H, C₆H₅), 5.78 (ddd J=16.5, 11.2, 7.5Hz, 1H, CH=CH₂), 5.13 (app dt, *J*=11.2, 1.2Hz, CH=CHH), 5.11 (app dt, *J*=16.5, 1.2Hz, 1H, CH=CHH), 3.82 (d, *J*=11.3Hz, 1H, S-CH), 3.53 (m. 2H, CH-N-CHH), 3.07 (m, 1H, N-CHH), 2.41 (m, 1H, N-CHCH), 1.90 (m, 3H, CH₂CHH), 1.18 (m, 1H, CH₂CHH); ¹³C NMR (100.58 MHz, CDCl₃) δ 171.2, 135.6, 133.4, 129.0, 128.8, 127.8, 118.2, 63.5, 58.8, 53.2, 42.1, 30.7, 26.3; MS (70eV) *m/z* (M⁺)259, 150, 121, 109, 81, 70, 53, 41.
- (8) Spectral data for Cyclopropane 10: ¹H NMR (400 MHz, CDCl₃) δ 7.30 7.15 (m, 5H, -C₆H₅), 4.06 (dt, *J* = 9.5, 5.7 Hz, 1H, N-CH-), 3.26 (dd, *J* = 13.4, 4.9 Hz, 1H, S-CHH-), 3.18 (dt, *J* = 11.5, 8.1 Hz, 1H, N-CHH-), 2.93 (m, 1H, N-CHH-), 2.47 (dd, *J* = 13.4, 9.2 Hz, 1H, S-CHH-), 1.99 (m, 3H, -CH₂-CHH-), 1.82 (m, 1H, N-CO-CH-), 1.63 (m, 1H, -CH₂-CHH-), 1.24 (m, 1H, N-CH-CH-), 1.14 (m, 1H, S-CH₂-CH-); ¹³C NMR (100.58 MHz, CDCl₃) δ 173.2, 135.3, 130.5, 128.9, 126.7, 61.8, 40.9, 36.0, 32.2, 28.0, 27.4, 21.1, 20.9; IR (neat) 1694, 1651; MS (70 eV) *m/z* (M⁺)259, 182, 150, 136, 120, 94, 79, 70, 53; High Resolution MS *m/z* calculated for C₁₅H₁₇NOS (M⁺) 259.1031, found 259.1023.
 Cyclopropane 11: ¹H NMR (400 MHz, CDCl₃) δ 7.39 7.19 (m, 5H, -C₆H₅), 3.57 (dt, *J* = 11.6, 8.2 Hz, 1H, N-CHH-), 3.46 (dd, *J* = 10.8, 4.0 Hz, 1H, N-CH-), 3.11 (dd, *J* = 13.6, 5.2 Hz, 1H, S-CHH-), 2.85 (m, 1H, N-CHH-), 2.58 (dd, *J* = 13.6, 8.4 Hz, 1H, S-CHH-), 1.55 (m, 1H, S-CH₂-CH-), 1.15 (dd, *J* = 10.8, 8.8 Hz, 1H, N-CH-), ^{1.3C} NMR (100.58 MHz, CDCl₃) δ 177.5, 135.4, 130.4, 129.0, 126.7, 63.5, 42.0, 36.5, 29.8, 28.7, 28.2, 27.6, 24.9; IR (neat) 1694, 1598; MS (70 eV) *m/z* (M⁺)259.1031, found 259.1023.

(Received in USA 14 February 1996; revised 18 July 1996; accepted 19 July 1996)